Immunoglobulin A
Efficacy and Safety of Telitacicept in IgA Nephropathy Shown in Study
Researchers at Affiliated to Shanghai Jiao Tong University School of Medicine have conducted a study to evaluate the effectiveness and safety of telitacicept in patients with IgA nephropathy (IgAN). The study, which included 33 IgAN patients, found that telitacicept treatment for at least 3 months resulted in a significant reduction